NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Mai Peptide

Published 12 Nov 2026. 37-page investigative report on who is behind Mai Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Mai Peptide is an uneven vendor, not a simple pass/fail story. Across 125 Finnrick lab tests the record is 87 pass / 38 fail, an overall pass rate of 70%. Retatrutide and GHK-Cu carry the more defensible signal, while BPC-157 is a weak line and Tirzepatide deserves separate caution because the file includes a zero-labelled-API vial note. Under stricter grading, several mixed-looking lines become less forgiving.

The business layer is more opaque than the product catalogue. The current storefront is active and stocked, but it does not name a legal seller, registration number, manufacturer, QA lead or batch-release authority. The best-supported operating trail points toward a Xi'an/Shaanxi B2B network with Hong Kong-numbered sales contacts, while public registry searches did not resolve the retail operation's legal seller or UBO.

The report also separates real evidence from sales gloss: Freedom Diagnostics COAs were located, but outside the official site, with cap colours standing in for lot identifiers; the official COA page was empty. Payment and channel evidence is materially messy: crypto-only checkout, a representative Carrd promoting Alibaba/Wise/WU/Cash App-style rails and a concealment instruction, plus forum sponsorship, Telegram promotion, lookalike domains and disposable review pages.

For buyers, the read is product-specific: Mai may be more reasonable only on its stronger-tested lines and only with current lot-matched proof. The full report shows exactly which channels, COAs, domain names and payment paths Finnrick could verify, and which remain unresolved.

Inside the full report:

  • Appendix A per-product pass/fail rates and methodology-divergence charts for all 11 products
  • RDAP and infrastructure analysis covering Mai-Peptides, MaiPeptide, Mai-Peptide, TIRZ-PEPTIDE, SKWBIO and adjacent template sites
  • Freedom Diagnostics COA traceability review, including Carrd-hosted PDFs and cap-colour lot fields
  • Corporate identity trail across Xi'an/Shaanxi B2B records, Hong Kong sales contacts and unresolved registry/UBO searches
  • Payment-rail and buyer-recourse analysis covering crypto checkout, Carrd off-platform instructions and delivery complaints
  • Promotion-network analysis covering sponsor-forum threads, Telegram, TikTok, Reddit-style posts and parasite SEO pages

Risk assessment

  • Product-specific weak-line quality risk — high: BPC-157 47.82% (3/7), NAD+ 24.99% (1/3), TB-500 34.62% (1/4), CJC-1295 36.49% (2/3) and Semaglutide 54.11% with 0/3 pass are poor directional choices from Mai.
  • Tirzepatide identity risk — high: Tirzepatide is 62.99% with 17/29 pass and carries a 2025-11-25 Finnrick field note of a vial containing zero labelled API.
  • Lot-traceability risk — high: Mai's on-site COA page is empty, product pages show no batch/lot field, and located Freedom Diagnostics COAs use cap colours rather than vial-matching lot numbers.
  • Payment-recourse and concealment risk — high: Official checkout lists BTC/USDT/USDC only; a sales-rep Carrd promotes Alibaba/WU/Wise/Alipay/Cash App/crypto and instructs buyers not to mention peptides on Alibaba.
  • Telegram/WhatsApp fraud and non-delivery risk — medium: Trustpilot and Reddit allegations describe fake tracking, a Bitcoin customs-release demand, blocking, non-response and a $540 loss; allegations are not independently verified but fit the channel design.
  • Copycat and brand-confusion risk — medium: maipeptide.com is parked, mai-peptide.com is a live WooCommerce lookalike, and meipeptide.com/miapeptides.com add confusion; Mai publishes no official-channel or authorized-reseller list.
  • Legal seller / UBO opacity risk — medium: The storefront names no legal entity, registration number or address; Chinese registry and UBO searches did not retrieve primary shareholder, director or legal-representative records.
  • Affiliate-promotion risk — medium: Mai appears in forum sponsorship, Telegram promotion, sales-rep social channels, comment spam and disposable parasite-SEO review pages; disclosure is uneven and direct control is not proven for every asset.
  • Manufacturer and QA claim-verification risk — medium: The About page claims own R&D labs and production lines, while the attributed Echemi entity is listed as a small Trader; Mai names no manufacturer, facility or QA lead.